Timeline for Tenure and Promotion Process Sample Clauses

The "Timeline for Tenure and Promotion Process" clause establishes the specific schedule and deadlines for each stage of evaluating faculty members for tenure and promotion. It typically outlines when applications must be submitted, the periods for departmental and committee reviews, and the final decision dates. By providing a clear sequence of events and timeframes, this clause ensures transparency and predictability in the process, helping both faculty and administrators manage expectations and responsibilities.
Timeline for Tenure and Promotion Process. 6.6.8.1 Application for Tenure and/or Promotion shall be made in writing by the Member. It is the responsibility of the Member to initiate the application process. 6.6.8.2 With the exception of alternative dates established by mutual consent of the Member and the University, the following timeline shall be adhered to in all Tenure and/or Promotion applications and decision- making: (a) By 15 May prior to the academic year during which a Member’s application will be reviewed, the ▇▇▇▇/Director notifies in writing all Members in their Division, Faculty or School who are eligible to apply for Tenure as per Article 6.3.1. A notice shall be placed on the University web site announcing a September 1 deadline for applications for Tenure and Promotion. (b) By 1 August, Members shall notify their Chair of their application for Tenure and/or Promotion. Within five working days, the Chair shall provide the ▇▇▇▇/Director with a list of Members who will submit an application. (c) By 1 September, Members shall submit their application portfolio to the Chair of the appropriate DPTC. (d) By 15 December, the Chair of the DPTC shall forward to the Chair of the UPTC the complete application file and the recommendation of the Committee with reasons. (e) By 28 February, the Chair of the UPTC shall forward to the President for review and decision the complete application file, the recommendation of the DPTC and the recommendation of the UPTC with reasons. (f) By 31 March, the President shall notify the Member of his/her decision.
View SourceView Similar (5)

Related to Timeline for Tenure and Promotion Process

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Schedule The Project shall substantially comply with the specific timetables and triggers for action set forth in Article 5 of this Agreement. The parties acknowledge that, as provided in G.S. 160A-400.25(b), the failure to meet a commencement or completion date shall not, in and of itself, constitute a material breach of this Agreement pursuant to G.S. 160A-400.27 but must be judged based upon the totality of the circumstances.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.